A microRNA expression signature of human solid tumors defines cancer gene targets S Volinia, GA Calin, CG Liu, S Ambs, A Cimmino, F Petrocca, R Visone, ... Proceedings of the National Academy of Sciences 103 (7), 2257-2261, 2006 | 7343 | 2006 |
MicroRNA signatures in human ovarian cancer MV Iorio, R Visone, G Di Leva, V Donati, F Petrocca, P Casalini, C Taccioli, ... Cancer research 67 (18), 8699-8707, 2007 | 1938 | 2007 |
Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1713 | 2021 |
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ... New England Journal of Medicine 380 (18), 1726-1737, 2019 | 1545 | 2019 |
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis M Bloomston, WL Frankel, F Petrocca, S Volinia, H Alder, JP Hagan, ... Jama 297 (17), 1901-1908, 2007 | 1545 | 2007 |
E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer F Petrocca, R Visone, MR Onelli, MH Shah, MS Nicoloso, I de Martino, ... Cancer cell 13 (3), 272-286, 2008 | 1159 | 2008 |
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer S Ambs, RL Prueitt, M Yi, RS Hudson, TM Howe, F Petrocca, TA Wallace, ... Cancer research 68 (15), 6162-6170, 2008 | 931 | 2008 |
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle R Visone, L Russo, P Pallante, I De Martino, A Ferraro, V Leone, ... Endocrine-related cancer 14 (3), 791-798, 2007 | 569 | 2007 |
Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor β signaling F Petrocca, A Vecchione, CM Croce Cancer research 68 (20), 8191-8194, 2008 | 504 | 2008 |
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas R Visone, P Pallante, A Vecchione, R Cirombella, M Ferracin, A Ferraro, ... Oncogene 26 (54), 7590-7595, 2007 | 475 | 2007 |
miR-200 enhances mouse breast cancer cell colonization to form distant metastases DM Dykxhoorn, Y Wu, H Xie, F Yu, A Lal, F Petrocca, D Martinvalet, ... PloS one 4 (9), e7181, 2009 | 402 | 2009 |
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma MK Samur, M Fulciniti, A Aktas Samur, AH Bazarbachi, YT Tai, ... Nature communications 12 (1), 868, 2021 | 258 | 2021 |
A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells F Petrocca, G Altschuler, SM Tan, ML Mendillo, H Yan, DJ Jerry, AL Kung, ... Cancer cell 24 (2), 182-196, 2013 | 226 | 2013 |
Promise and challenge of RNA interference–based therapy for cancer F Petrocca, J Lieberman Journal of Clinical Oncology 29 (6), 747-754, 2011 | 183 | 2011 |
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer AE Witt, CW Lee, TI Lee, DJ Azzam, B Wang, C Caslini, F Petrocca, ... Oncogene 36 (12), 1707-1720, 2017 | 162 | 2017 |
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. NC Munshi, LD Anderson, Jr, N Shah, S Jagannath, JG Berdeja, S Lonial, ... Journal of Clinical Oncology 38 (15_suppl), 8503-8503, 2020 | 131 | 2020 |
miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes R Perdigao-Henriques, F Petrocca, G Altschuler, MP Thomas, MTN Le, ... Oncogene 35 (2), 158-172, 2016 | 128 | 2016 |
Gene knockdown by EpCAM aptamer–siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells A Gilboa-Geffen, P Hamar, MTN Le, LA Wheeler, R Trifonova, F Petrocca, ... Molecular cancer therapeutics 14 (10), 2279-2291, 2015 | 93 | 2015 |
bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. NS Raje, JG Berdeja, Y Lin, NC Munshi, DSDC Siegel, M Liedtke, ... Journal of Clinical Oncology 36 (15_suppl), 8007-8007, 2018 | 91 | 2018 |
Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy P Sridhar, F Petrocca Cancers 9 (7), 92, 2017 | 88 | 2017 |